TEK 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for TEK is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
55 Direct drug records from Target & Disease MCP | 36 Development records in target context | 406 Disease associations captured | 918 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
TEK / Tie-2 regulates vascular stability and angiopoietin signaling
Target & Disease MCP resolves TEK to Tie-2, an endothelial receptor for ANGPT1, ANGPT2, and ANGPT4. It regulates angiogenesis, endothelial survival, migration, adhesion, actin reorganization, vascular quiescence, anti-inflammatory barrier effects, heart development, hematopoiesis, PI3K-AKT, FAK, MAPK, DOK2, GRB7, GRB14, SHC1, and TIE1 signaling.
Validation is pathway-rich but context-dependent
The MCP workflow retrieved 55 direct drug records, 36 development records, and 406 disease associations. Clinical Trials MCP returned 918 records. Because Tie-2 can promote stability in quiescent vessels or sprouting in migratory endothelial states, indication context is crucial.
Clinical competition includes vascular and multikinase programs
Recent records include regorafenib plus sintilimab/radiotherapy in GIST, QL1706 plus radiotherapy in HCC, and Exelixis extension studies. These provide vascular-pathway and multikinase readouts rather than only Tie-2-selective evidence.
IP and strategy view
TEK IP should center on Ang1/Ang2 biology, vascular normalization, ocular or oncology context, and combinations where vascular stabilization improves efficacy.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 918 registered trial records connected to TEK. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Regorafenib plus sintilimab and radiotherapy versus regorafenib in advanced GIST | Phase 3 | Not yet recruiting |
| Radiotherapy plus iparomlimab and tuvonralimab in advanced unresectable HCC | Phase 2 | Not yet recruiting |
| Long-term extension study for participants in an Exelixis-sponsored study | Phase 3 | Not yet recruiting |
R&D Strategy Recommendation
TEK should be evaluated as a vascular-state target. The strongest strategy is to define when angiopoietin/Tie-2 modulation stabilizes vessels, improves delivery, or changes immune access.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
